ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

Sabine Schmid, Georgia Dimopoulou, Paul van Schil, David König, Laetitia Mauti, Malinda Itchins, Martin Früh, Kersti Oselin, Lorenza Landi, Maurice Pérol, Sanjay Popat, Clemens Aigner, Patrick Forde, Wouter K. de Jong, Heidi Roschitzki-Voser, Eva Grolimund, Barbara Ruepp, Benjamin Solomon, Stephen Finn, Urania Dafni, Rolf Stahel, Solange Peters

Open source

DOI: 10.1016/j.lungcan.2025.108635
Published: 2025-08
Container: Lung Cancer
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2025.108635,
  title = {ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC},
  author = {Sabine Schmid and Georgia Dimopoulou and Paul van Schil and David König and Laetitia Mauti and Malinda Itchins and Martin Früh and Kersti Oselin and Lorenza Landi and Maurice Pérol and Sanjay Popat and Clemens Aigner and Patrick Forde and Wouter K. de Jong and Heidi Roschitzki-Voser and Eva Grolimund and Barbara Ruepp and Benjamin Solomon and Stephen Finn and Urania Dafni and Rolf Stahel and Solange Peters},
  year = {2025},
  journal = {Lung Cancer},
  doi = {10.1016/j.lungcan.2025.108635},
  url = {https://doi.org/10.1016/j.lungcan.2025.108635}
}

RIS

TY  - JOUR
TI  - ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
AU  - Sabine Schmid
AU  - Georgia Dimopoulou
AU  - Paul van Schil
AU  - David König
AU  - Laetitia Mauti
AU  - Malinda Itchins
AU  - Martin Früh
AU  - Kersti Oselin
AU  - Lorenza Landi
AU  - Maurice Pérol
AU  - Sanjay Popat
AU  - Clemens Aigner
AU  - Patrick Forde
AU  - Wouter K. de Jong
AU  - Heidi Roschitzki-Voser
AU  - Eva Grolimund
AU  - Barbara Ruepp
AU  - Benjamin Solomon
AU  - Stephen Finn
AU  - Urania Dafni
AU  - Rolf Stahel
AU  - Solange Peters
PY  - 2025
JO  - Lung Cancer
DO  - 10.1016/j.lungcan.2025.108635
UR  - https://doi.org/10.1016/j.lungcan.2025.108635
ER  -

APA

Schmid, S., Dimopoulou, G., Schil, P. V., König, D., Mauti, L., Itchins, M., Früh, M., Oselin, K., Landi, L., Pérol, M., Popat, S., Aigner, C., Forde, P., Jong, W. K. D., Roschitzki-Voser, H., Grolimund, E., Ruepp, B., Solomon, B., Finn, S., Dafni, U., Stahel, R., & Peters, S. (2025). ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC. Lung Cancer. https://doi.org/10.1016/j.lungcan.2025.108635

Source records

crossref · retrieved 2026-09-27T07:49:28.490Z